Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated traditional Chinese and western medicine nutritional support in neoadjuvant treatment for rectal cancer
ChiCTR2300075127Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of bazhengsan in rectal cancer (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Tumor downstaging rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
bazhengsan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2300075127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075127.